Skip to main content

Interventions for Bowen's disease: A systematic review and network meta-analysis of randomized controlled trials.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG2025-08-19PubMed
Total: 78.5Innovation: 8Impact: 0Rigor: 0Citation: 0

Summary

Across nine RCTs, laser-assisted photodynamic therapy ranked highest for initial clearance, surgery for long-term clearance, and PDT/LA-PDT/5-FU achieved the most favorable cosmetic outcomes. Cryotherapy and imiquimod ranked lowest for both initial and long-term clearance. The review was PROSPERO-registered and used Cochrane risk-of-bias assessments, though heterogeneity and bias were noted.

Key Findings

  • LA-PDT ranked first for initial lesion clearance; surgery and laser ablation followed.
  • Surgery ranked first for long-term clearance; LA-PDT and PDT followed.
  • PDT, LA-PDT, and 5-FU had the best cosmetic outcomes; surgery had the worst.
  • Cryotherapy and imiquimod ranked lowest for both initial and long-term clearance.

Clinical Implications

For lesions where cosmesis matters, PDT or LA-PDT can be prioritized; if durable long-term clearance is paramount, surgery remains preferred. Counseling should address the trade-offs, particularly the lower clearance with cryotherapy or imiquimod.

Why It Matters

This is the first network meta-analysis to rank Bowen's disease interventions by both efficacy and cosmetic outcomes, directly informing shared decision-making.

Limitations

  • Moderate-to-high risk of bias and heterogeneity across included trials
  • Limited number of head-to-head comparisons and variable outcome definitions

Future Directions

Conduct adequately powered head-to-head RCTs (e.g., LA-PDT vs surgery vs PDT) with standardized cosmetic outcome measures and long-term follow-up.

Study Information

Study Type
Systematic Review/Meta-analysis
Research Domain
Treatment
Evidence Level
I - Systematic review and network meta-analysis of randomized controlled trials
Study Design
OTHER